^Ridker, Paul M; Devalaraja, Matt; Baeres, Florian M M; Engelmann, Mads D M; Hovingh, G Kees; Ivkovic, Milana; Lo, Larry; Kling, Douglas; Pergola, Pablo; Raj, Dominic; Libby, Peter; Davidson, Michael (May 2021). "IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial". The Lancet. 397 (10289): 2060–2069.
doi:
10.1016/S0140-6736(21)00520-1.
PMID34015342.
S2CID235073253.
^Ridker, Paul M; Devalaraja, Matt; Baeres, Florian M M; Engelmann, Mads D M; Hovingh, G Kees; Ivkovic, Milana; Lo, Larry; Kling, Douglas; Pergola, Pablo; Raj, Dominic; Libby, Peter; Davidson, Michael (May 2021). "IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial". The Lancet. 397 (10289): 2060–2069.
doi:
10.1016/S0140-6736(21)00520-1.
PMID34015342.
S2CID235073253.